Your session is about to expire
← Back to Search
This trial is testing whether a specific drug combination of ZEN-3694 and talazoparib works to shrink tumors in patients with advanced solid tumors. Another aim of this study is to find out if, and how, patients' genes influence their response to this drug combination.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 3 trial • 431 Patients • NCT01945775
Awards & Highlights
Find a Location
Who is running the clinical trial?
- Group 1: Treatment (ZEN-3694, talazoparib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the recruitment of participants for this experiment ongoing?
"That is correct. According to information posted on clinicaltrials.gov, this medical trial was initially submitted on August 4th 2022 and has since been updated on November 3rd 2022. The study necessitates 88 participants from a selection of four locations."
What is the total cohort size of this clinical trial?
"The clinical trial necessitates the recruitment of 88 qualified individuals. Potential participants can join from medical centres like Emory University Hospital/Winship Cancer Institute in Atlanta, Georgiap Cancer Institute in Atlanta, Georgia and M D Anderson Cancer Center in Houston, Texas."
Has the U.S. Food and Drug Administration sanctioned ZEN-3694 as a BET Bromodomain Inhibitor?
"Our evaluative team has granted BET Bromodomain Inhibitor ZEN-3694 a score of 2 due to the fact that, while there is some data suggesting safety, this experiment remains in Phase 2 and therefore lacks efficacy evidence."
Share this study with friends